| Attribute |
Value |
| 52 Week Change |
0.009523869 |
| Address1 |
19,805 North Creek Parkway |
| All Time High |
1,440.0 |
| All Time Low |
0.76 |
| Ask |
1.49 |
| Ask Size |
2 |
| Average Analyst Rating |
1.0 - Strong Buy |
| Average Daily Volume10 Day |
35,730 |
| Average Daily Volume3 Month |
55,522 |
| Average Volume |
55,522 |
| Average Volume10Days |
35,730 |
| Beta |
1.482 |
| Bid |
0.8208 |
| Bid Size |
2 |
| Book Value |
0.076 |
| City |
Bothell |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
1.08 |
| Current Ratio |
1.237 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,790,726,400 |
| Day High |
1.1099 |
| Day Low |
1.02 |
| Debt To Equity |
128.448 |
| Display Name |
Cocrystal Pharma |
| Dividend Date |
1,516,752,000 |
| Dividend Yield |
0.0 |
| Earnings Timestamp End |
1,755,084,600 |
| Earnings Timestamp Start |
1,755,084,600 |
| Ebitda |
-10,060,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-1.986 |
| Enterprise To Revenue |
60.534 |
| Enterprise Value |
19,976,256 |
| Eps Current Year |
-0.725 |
| Eps Forward |
-0.475 |
| Eps Trailing Twelve Months |
-0.77 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
15 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
1.126 |
| Fifty Day Average Change |
-0.046000004 |
| Fifty Day Average Change Percent |
-0.040852576 |
| Fifty Two Week Change Percent |
0.95238686 |
| Fifty Two Week High |
2.03 |
| Fifty Two Week High Change |
-0.9499999 |
| Fifty Two Week High Change Percent |
-0.46798027 |
| Fifty Two Week Low |
0.76 |
| Fifty Two Week Low Change |
0.32000005 |
| Fifty Two Week Low Change Percent |
0.4210527 |
| Fifty Two Week Range |
0.76 - 2.03 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,329,921,000,000 |
| Float Shares |
11,908,510 |
| Forward Eps |
-0.475 |
| Forward P E |
-2.2736843 |
| Free Cashflow |
-4,318,750 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
10 |
| Fullday Change |
0.03000009 |
| Fullday Change Percent |
2.8301973 |
| Fullday Price |
1.08 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.0 |
| Gross Profits |
-5,756,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.65712 |
| Held Percent Institutions |
0.057740003 |
| Implied Shares Outstanding |
19,263,200 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,665,446,400 |
| Last Split Factor |
1:12 |
| Long Business Summary |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington. |
| Long Name |
Cocrystal Pharma, Inc. |
| Market |
us_market |
| Market Cap |
20,804,256 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_49062639 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
-9,938,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
22,730,576 |
| Number Of Analyst Opinions |
3 |
| Open |
1.05 |
| Operating Cashflow |
-7,954,000 |
| Operating Margins |
-30.32381 |
| Payout Ratio |
0.0 |
| Phone |
877 262 7123 |
| Previous Close |
1.06 |
| Price Eps Current Year |
-1.4896551 |
| Price Hint |
4 |
| Price To Book |
14.210527 |
| Price To Sales Trailing12 Months |
63.0432 |
| Profit Margins |
0.0 |
| Quick Ratio |
1.11 |
| Quote Source Name |
Delayed Quote |
| Quote Type |
EQUITY |
| Recommendation Key |
strong_buy |
| Recommendation Mean |
1.0 |
| Region |
US |
| Regular Market Change |
0.0200001 |
| Regular Market Change Percent |
1.8868 |
| Regular Market Day High |
1.1099 |
| Regular Market Day Low |
1.02 |
| Regular Market Day Range |
1.02 - 1.1099 |
| Regular Market Open |
1.05 |
| Regular Market Previous Close |
1.06 |
| Regular Market Price |
1.08 |
| Regular Market Time |
1,791,921,601 |
| Regular Market Volume |
86,657 |
| Return On Assets |
-0.96072996 |
| Return On Equity |
-3.11683 |
| Revenue Per Share |
0.025 |
| Sand P52 Week Change |
0.17502642 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
19,263,200 |
| Shares Percent Shares Out |
0.0091 |
| Shares Short |
175,246 |
| Shares Short Previous Month Date |
1,788,134,400 |
| Shares Short Prior Month |
322,544 |
| Short Name |
Cocrystal Pharma, Inc. |
| Short Percent Of Float |
0.0111 |
| Short Ratio |
3.34 |
| Source Interval |
15 |
| State |
WA |
| Symbol |
COCP |
| Target High Price |
10.0 |
| Target Low Price |
6.0 |
| Target Mean Price |
8.0 |
| Target Median Price |
8.0 |
| Total Cash |
2,169,000 |
| Total Cash Per Share |
0.113 |
| Total Debt |
1,341,000 |
| Total Revenue |
330,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-0.77 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
1.10655 |
| Two Hundred Day Average Change |
-0.026549935 |
| Two Hundred Day Average Change Percent |
-0.023993436 |
| Type Disp |
Equity |
| Volume |
86,657 |
| Website |
https://www.cocrystalpharma.com |
| Zip |
98,011 |